Enavate Sciences is a corporate venture established by Patient Square Capital in May 2022, with an initial capital commitment of $300 million. The firm invests in and provides strategic growth support to innovative therapeutic and enabling technology companies, focusing on advancing novel therapies in pre-clinical and clinical stages.
100% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $194.9M (across 3 rounds with reported amounts).
Portfolio
4
Fund Size
—
Top Stage
Series A
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Braveheart Bio | Series A | $185M | Nov 2025 |
 BridgeBio Oncology Therapeutics (BBOT) | Growth | $200M | May 2024 |
| GGraviton Bioscience | Unknown | — | Jan 2024 |
 Aviceda Therapeutics | Series C | $199.6M | — |
Top Co-Investors
OrbiMed2 shared
Omega Funds2 shared
Andreessen Horowitz1 shared
Forbion1 shared
Frazier Life Sciences1 shared
GV (Google Ventures)1 shared
Wellington Management1 shared
Cormorant Asset Management1 shared
Deerfield1 shared
Surveyor Capital1 shared
Casdin Capital1 shared
Longwood Fund1 shared
Longitude Capital1 shared
Logos Capital1 shared
Marshall Wace1 shared
Catalio Capital Management1 shared
funds managed by abrdn Inc.1 shared
Digitalis Ventures1 shared
Jeito Capital1 shared
Last updated: 16 April 2026